Memorial Sloan-Kettering

This Week in Cell

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.

Researchers found that ADAR works by stabilizing the FAK gene, which is one of a subset involved in cell migration pathways.

Not Yet for Watson

Stat News reports that IBM's Watson for Oncology isn't yet living up to its promise.

This small, for-profit Dutch company has been a driving force behind freeing cBioPortal from Memorial Sloan Kettering, as well as continued development of the software.

Philips has teamed with Illumina and Intermountain Healthcare's Navican on informatics for precision medicine and signed a genome analytics deal with Memorial Sloan Kettering Cancer Center.

The company hopes to raise funding this summer and has been conducting pilots with NewYork-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center.

This Week in Nature

In Nature this week: variability in iPSCs, the silver birch, and more.

More than a third of the first 10,000 patients receiving MSK-IMPACT harbored actionable mutations, and 11 percent of the first 5,000 enrolled in a clinical trial. 

The amount of cancer data being generated is driving researchers to develop artificial intelligence and deep machine-learning methods to help them keep up.

Speakers at the conference's opening plenary showed how their work in cancer research fit into the broad theme of 'Discover, Predict, Prevent, Treat.'

Pages

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.